P142 Results of the 3rd interim analysis of C-Patrol: a non-interventional study on olaparib in german routine clinical practice
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.204
Abstract: Introduction/Background Olaparib (50 mg hard capsules, HC) was the 1st PARPi approved in the EU in 12/2014 as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) ovarian cancer (PSR-OC) who are… read more here.
Keywords: 3rd interim; interim analysis; clovis; roche ... See more keywords